Zealand Pharma

Zealand Pharma

Zealand Pharma was founded in 1998 in Denmark as a peptide-focused discovery platform, spinning out of the Danish biotech ecosystem. The firm has transitioned from a contract-research organization to a fully integrated biopharma company, with a focus on metabolic and gastrointestinal diseases. Its early peptide-engineering expertise remains the core IP. The company's investment thesis centers on novel peptide therapeutics, with two approved products: liraglutide (a GLP-1 analog) for type 2 diabetes and obesity, and pramlintide (an amylin analog) for diabetes. Zealand has built a pipeline spanning preclinical to phase 3, including the dual GLP-1/amylin agonist ZP8396, which targets obesity with a differentiated mechanism. The firm partners with large pharma (e.g., Boehringer Ingelheim on the GLP-1 franchise) and has a wholly owned development arm in the US, with offices in Boston. Geographic reach is global via partners, but its own operations center in Europe and North America. Zealand employs approximately 400 people, with R&D and commercial staff split between Hellerup (HQ) and Boston. In 2024, the company raised $500M in a convertible bond offering to fund its obesity pipeline (per the company, June 2024). It does not operate as a family office, asset manager, or wealth vehicle — it is a publicly traded biotech (NASDAQ: ZEAL) with no external capital under management. The firm has no philanthropic or adjacent-vehicle disclosures beyond its public company structure. Zealand Pharma’s structural differentiator is its deep peptide-engineering history and its focus on dual-agonist mechanisms in metabolic disease — a strategy that borrows from the Novo Nordisk playbook but targets different and potentially safer pathways. The firm’s mandate is entirely therapeutic, not financial; it deploys capital into R&D, commercial infrastructure, and partnerships, not into investment portfolios. Its governance follows a standard public-company board structure.